PT  - JOURNAL ARTICLE
AU  - Sun, Xingzhi
AU  - De Brouwer, Edward
AU  - Liu, Chen
AU  - Krishnaswamy, Smita
AU  - Batra, Ramesh
TI  - Deep Learning Unlocks the True Potential of Organ Donation after Circulatory Death with Accurate Prediction of Time-to-Death
AID  - 10.1101/2024.11.07.24316924
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.07.24316924
4099  - http://medrxiv.org/content/early/2024/11/08/2024.11.07.24316924.short
4100  - http://medrxiv.org/content/early/2024/11/08/2024.11.07.24316924.full
AB  - Increasing the number of organ donations after circulatory death (DCD) has been identified as one of the most important ways of addressing the ongoing organ shortage. While recent technological advances in organ transplantation have increased their success rate, a substantial challenge in increasing the number of DCD donations resides in the uncertainty regarding the timing of cardiac death after terminal extubation, impacting the risk of prolonged ischemic organ injury, and negatively affecting post-transplant outcomes. In this study, we trained and externally validated an ODE-RNN model, which combines recurrent neural network with neural ordinary equations and excels in processing irregularly-sampled time series data. The model is designed to predict time-to-death following terminal extubation in the intensive care unit (ICU) using the last 24 hours of clinical observations. Our model was trained on a cohort of 3,238 patients from Yale New Haven Hospital, and validated on an external cohort of 1,908 patients from six hospitals across Connecticut. The model achieved accuracies of 95.3 ± 1.0% and 95.4 ± 0.7% for predicting whether death would occur in the first 30 and 60 minutes, respectively, with a calibration error of 0.024 ± 0.009. Heart rate, respiratory rate, mean arterial blood pressure (MAP), oxygen saturation (SpO2), and Glasgow Coma Scale (GCS) scores were identified as the most important predictors. Surpassing existing clinical scores, our model sets the stage for reduced organ acquisition costs and improved post-transplant outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly funded by: HHS | National Institutes of Health (NIH) Valid 1F30AI157270-01: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy HHS | National Institutes of Health (NIH) Valid R01HD100035: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy HHS | National Institutes of Health (NIH) Valid R01GM130847: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy HHS | National Institutes of Health (NIH) Valid R01GM135929: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy Yale Innovation Grant : Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy, Ramesh Batra NSF Career grant 2047856: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy Chan-Zuckerberg Initiative CZF2019-182702: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy Chan-Zuckerberg Initiative CZF2019-002440: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy Sloan Fellowship FG-2021-15883: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita Krishnaswamy Novo Nordisk (Novo Nordisk Global) Valid GR112933: Xingzhi Sun, Edward De Brouwer, Chen Liu, Smita KrishnaswamyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University Institutional Review Board of Yale University waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe are not going to make the data available to the general public, protecting the privacy of patients, and sensitive nature of the data in line with HIPPA rules.